11 completed, 4 unknown, 3 recruiting, 1 active not recruiting. 5 Phase 2, 4 Not applicable, 4 Phase 1, 2 Phase 4, 1 Early Phase 1.
Follow Hormone Receptor Positive Malignant Neoplasm of Breast: new trials by email Literature Review of Hormone Receptor Positive Malignant Neoplasm of Breast trials Research Report on Hormone Receptor Positive Malignant Neoplasm of Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Revaree Plus in People With Breast Cancer Revaree Plus - Breast Cancer, Stage 0 Breast Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2025-06-20 | 2026-02-06 |
| BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors BGB-43395, Fulvestrant, Letrozole - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Completed | BeOne Medicines | 33 | 2024-04-01 | 2026-06-10 |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors BGB-43395, Fulvestrant, Letrozole - Advanced Solid Tumor, Advanced Breast Cancer | Phase 1 | Recruiting | BeOne Medicines | 433 | 2023-12-01 | 2026-10-15 |
| Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study Palbociclib, Ribociclib, Abemaciclib - Breast Adenocarcinoma, Breast Cancer Stage IV | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 3500 | 2023-05-01 | 2025-02-03 | |
| Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. Combination, Rogaratinib + palbociclib + fulvestrant - Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast | Phase 1 | Completed | Fundacion CRIS de Investigación para Vencer el Cáncer | 9 | 2020-11-25 | 2023-12-28 |
| Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer Pyrotinib, Trastuzumab, Aromatase Inhibitors - Breast Cancer Female, HER2-positive Breast Cancer | Phase 2 | Unknown | Fuzhou General Hospital | 77 | 2019-11-01 | 2019-09-12 |
| Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer Abemaciclib, durvalumab and aromatase inhibitor - Breast Cancer Female, Locally Advanced Breast Cancer | Early Phase 1 | Withdrawn | Alison Stopeck | 2019-10-01 | 2020-07-16 | |
| Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer MRI - Breast Cancer, HER2-positive Breast Cancer | Not applicable | Active not recruiting | Brigham and Women's Hospital | 214 | 2019-07-26 | 2026-09-09 |
| Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer Palbociclib, Endocrine therapy - Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast | Phase 3 | Completed | Kyoto Breast Cancer Research Network | 141 | 2019-07-16 | 2023-03-10 |
| Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC Pyrotinib, Trastuzumab, Aromatase inhibitor - Breast Cancer Female, HER2-positive Breast Cancer | Phase 2 | Unknown | Peking Union Medical College Hospital | 250 | 2019-06-01 | 2019-04-10 |
| Prospective Thinking in Hormone-Responsive Breast Cancer Episodic future thinking, Episodic recent thinking - Hormone Receptor Positive Malignant Neoplasm of Breast | Not applicable | Completed | Virginia Polytechnic Institute and State University | 89 | 2018-08-01 | 2019-10-01 |
| Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer RAD140 - Hormone Receptor Positive Malignant Neoplasm of Breast | Phase 1 | Completed | Stemline Therapeutics, Inc. | 20 | 2017-10-23 | 2022-08-18 |
| Comparison of the Breast Tumor Microenvironment Breast tissue collection, Blood sample collection - Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast | Completed | Columbia University | 14 | 2017-09-28 | 2026-10-21 | |
| Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Palbociclib, Tamoxifen - Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | Completed | Oana Danciu, MD | 49 | 2017-02-01 | 2026-01-20 |
| The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population Questionnaires, Oncotype Dx Assay - Hormone Receptor Positive Malignant Neoplasm of Breast | Not applicable | Completed | Sunnybrook Health Sciences Centre | 100 | 2014-10-01 | 2020-10-23 |
| Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab Bevacizumab, Capecitabine, Everolimus - Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast | Phase 4 | Completed | iOMEDICO AG | 85 | 2014-08-01 | 2017-11-13 |
| Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane Everolimus plus Exemestane - Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer | Not applicable | Unknown | Amsterdam UMC, location VUmc | 175 | 2014-03-01 | 2019-10-14 |
| PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score MammaPrint - Hormone Receptor Positive Malignant Neoplasm of Breast | Completed | Agendia | 820 | 2012-05-01 | 2016-01-29 | |
| Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer Metformin, Placebo - Hormone Receptor Positive Malignant Neoplasm of Breast | Phase 2 | Completed | Seoul National University Hospital | 208 | 2012-05-01 | 2018-09-10 |
| Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer Exemestane, Everolimus - Hormone Receptor Positive Malignant Neoplasm of Breast | Phase 2 | Unknown | Organisation for Oncology and Translational Research | 35 | 2014-01-01 |
Breast Neoplasms (12) · Neoplasm Metastasis (4) · Breast Diseases (3) · Triple Negative Breast Neoplasms (2) · Breast Carcinoma In Situ (1) · Breast Neoplasms, Male (1) · Inflammatory Breast Neoplasms (1)
Neoplasms (13) · Neoplasms by Site (13) · Skin Diseases (13) · Skin and Connective Tissue Diseases (13) · Breast Diseases (10) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma in Situ (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
exemestane (5) · Letrozole (4) · palbociclib (4) · Aromatase Inhibitors (3) · Everolimus (3) · Fulvestrant (3) · Anastrozole (2) · Drug Evaluation (2) · Trastuzumab (2) · abemaciclib (2) · pyrotinib (2) · Bevacizumab (1) · Capecitabine (1) · Magnetic Resonance Imaging (1) · Metformin (1)
BeOne Medicines (2) · Agendia (1) · Alison Stopeck (1) · Amsterdam UMC, location VUmc (1) · Brigham and Women's Hospital (1) · Columbia University (1) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (1) · Fundacion CRIS de Investigación para Vencer el Cáncer (1) · Fuzhou General Hospital (1) · Kyoto Breast Cancer Research Network (1) · Memorial Sloan Kettering Cancer Center (1) · Oana Danciu, MD (1) · Organisation for Oncology and Translational Research (1) · Peking Union Medical College Hospital (1) · Seoul National University Hospital (1)
United States (9) · China (4) · South Korea (3) · Australia (2) · Japan (2) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · Malaysia (1) · Moldova (1) · Netherlands (1) · New Zealand (1)
Alison Stopeck, MD (1) · Andrea Eisen, MD (1) · Ayal Aizer, MD, MHS (1) · Chen Xi, PhD (1) · Eileen Connolly, MD (1) · Epie Boven, Prof.dr. MD (1) · Jeff S Stein, PhD (1) · Lea Baer, MD (1) · Louis Chow (1) · Louis WC Chow, MD,PhD (1) · Luis Manso, MD (1) · Masakazu Toi, MD,PhD (1) · Michaela Tsai, MD (1)
PMID 24612502, PMID 32660609, PMID 34323542, PMID 40888443
2019 (1), 2023 (1)